All In MedTech

Device Trial Radar · NCT04398030

Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")

Randomized Crossover Euglycemic Clamp Study in Adult Patients With T1DM to Assess Pharmacokinetics and Pharmacodynamics of Subcutaneously Infused Insulin Using an Investigational Extended Wear Continuous Subcutaneous Insulin Infusion Cannula Compared to a Commercial Infusion Set

Last checked: Nov 20, 2026Latest source record: Aug 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

7

Actual

Start

Jul 17, 2020

Primary completion

Apr 22, 2021

Study completion Apr 22, 2021

Sponsor

Lead sponsor
Capillary Biomedical, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); AMCR Institute; Integrated Medical Development
First posted
May 21, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study has been designed as a prospectively enrolled, randomized sequence, 2-way crossover study of device performance, tolerability and safety of an investigational insulin infusion set using a coil-reinforced soft polymer indwelling cannula versus a commercial insulin infusion set using a soft Teflon indwelling cannula, during two 7-day home use periods with 4 in-clinic euglycemic clamp sessions during each of the 7-day periods. After a wash-out period, subjects will cross over into the investigational or control group, respectively.

Conditions

  • Diabetes Mellitus, Type 1
  • Type 1 Diabetes

Interventions

  • coil-reinforced soft polymer indwelling cannulaDevice

    Insulin infusion set will be used for up to 7 days of continuous use or until failure

  • soft Teflon indwelling catheterDevice

    Insulin infusion set will be used for up to 7 days of continuous use or until failure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Primary Endpoint is the Rate of Decline (s) Over Wear Time (DOI, Day 3, Day 5, Day 7) of the Natural Logarithm of the Area Under the Glucose Infusion Rate Curve [ln (AUC0-300(GIR))].Time frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • AMCR Institute

    Escondido, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.